QuidelOrtho (NASDAQ:QDEL) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

QuidelOrtho (NASDAQ:QDEL) issued its quarterly earnings data on Wednesday. The company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03, FiscalAI reports. QuidelOrtho had a positive return on equity of 5.75% and a negative net margin of 42.53%.The business had revenue of $723.60 million for the quarter, compared to analyst estimates of $699.80 million. During the same quarter in the prior year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis.

Here are the key takeaways from QuidelOrtho’s conference call:

• QuidelOrtho says it met 2025 guidance with $2.73 billion in revenue and Q4 revenue of $724 million, driven by mid-single-digit Labs growth and an expanded adjusted EBITDA margin of 22% (up 240 bps year‑over‑year).
• The company has realized $140 million in cost savings, reduced operating expenses 5%, and plans to continue margin expansion toward the mid‑20% EBITDA range through procurement, footprint optimization, and mix improvements.
• GAAP results include a $701 million non‑cash goodwill impairment recorded in Q3, which management says resets valuations but weighed on reported earnings (it does not affect cash operations).
• Cash flow and leverage remain a focus: Q4 free cash flow was hit by ~$45 million of timing items (collected in January), recurring FCF was ~$100 million for 2025, 2026 FCF guidance is $120–160 million, and net debt/adjusted EBITDA was 4.2x (guidance to ~3.8x at end‑2026 toward a 2.5–3.5x target).
• R&D momentum includes FDA clearances for high‑sensitivity Troponin I (VITROS) and the DAT card, launch of Results Manager middleware, and planned 2026 platform rollouts (VITROS 450 OUS, partner immunoassay systems, and the Lex molecular platform pending FDA/CLIA clearance), which management expects will drive future assay pulls and tender competitiveness.

QuidelOrtho Trading Down 1.4%

Shares of QuidelOrtho stock opened at $28.80 on Thursday. QuidelOrtho has a 52-week low of $19.50 and a 52-week high of $43.92. The firm has a market capitalization of $1.96 billion, a PE ratio of -1.69 and a beta of 0.68. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.78 and a quick ratio of 0.98. The company’s fifty day moving average price is $29.72 and its two-hundred day moving average price is $27.75.

Key Headlines Impacting QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: Revenue and top-line durability — Q4 revenue was reported at $723.6M, up ~2.2% year-over-year and modestly above consensus estimates, supporting the case for a more diversified, non-COVID revenue base. Press Release
• Positive Sentiment: Management guidance and cash flow outlook — management signaled continued growth and adjusted EBITDA margin expansion for FY26 and said free cash flow is expected to improve by more than $200M, which could support deleveraging and share valuation over time. Press Release
• Positive Sentiment: Insider buying and institutional activity — multiple insider purchases were reported in recent months and some large institutional buyers increased positions, which can be read as management confidence and institutional support. QuiverQuant
• Neutral Sentiment: Earnings call and transcript available — management discussed model details and strategy on the Q4 call; read the transcript/slide deck for guidance nuance and segment trends before making allocation changes. Earnings Call Transcript
• Negative Sentiment: EPS miss and margin pressure — EPS of $0.46 was below some consensus estimates (~$0.54), and the company reported negative net margin / operating losses on the quarter, highlighting ongoing profitability pressure despite revenue stability. MarketBeat Coverage
• Negative Sentiment: Mixed analyst sentiment and valuation risks — recent analyst notes include underweight/stressed price targets and a wide range of views (median ~$33, some as low as $22), reflecting uncertainty around margins, leverage and growth cadence. Analyst Summary

Insider Activity

In other QuidelOrtho news, CEO Brian J. Blaser bought 23,500 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average price of $21.34 per share, with a total value of $501,490.00. Following the completion of the purchase, the chief executive officer directly owned 29,533 shares in the company, valued at $630,234.22. The trade was a 389.52% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Joseph M. Busky purchased 4,770 shares of the business’s stock in a transaction on Monday, November 24th. The shares were acquired at an average price of $26.06 per share, with a total value of $124,306.20. Following the purchase, the chief financial officer owned 6,920 shares of the company’s stock, valued at approximately $180,335.20. This trade represents a 221.86% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 29,390 shares of company stock worth $657,340. 0.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On QuidelOrtho

Several hedge funds and other institutional investors have recently modified their holdings of QDEL. Invesco Ltd. boosted its stake in QuidelOrtho by 87.0% in the 3rd quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock valued at $85,604,000 after buying an additional 1,352,503 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of QuidelOrtho by 14.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company’s stock valued at $84,208,000 after purchasing an additional 350,636 shares in the last quarter. State Street Corp grew its holdings in shares of QuidelOrtho by 23.3% in the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company’s stock worth $77,841,000 after purchasing an additional 510,291 shares during the last quarter. Newtyn Management LLC increased its position in shares of QuidelOrtho by 58.3% during the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after purchasing an additional 994,332 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in QuidelOrtho by 101.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock valued at $50,134,000 after purchasing an additional 883,077 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on QDEL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, January 22nd. UBS Group boosted their target price on shares of QuidelOrtho from $31.00 to $35.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 21st. JPMorgan Chase & Co. lowered their price target on QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a research report on Friday, November 7th. Citigroup reiterated a “neutral” rating on shares of QuidelOrtho in a research note on Thursday. Finally, Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 13th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $39.00.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.